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ABSTRACT 
Objective:  Our research program has focused on the development of promising, soft alkylating N-phenyl-N’-(2-chloroethyl)urea (CEU) compounds 
which acylate the glutamic acid-198 of β-tubulin, near the binding site of colchicum alkaloids. CEUs inhibit the motility of cancerous cells in vitro 
and, interestingly, exhibit antiangiogenic and anticancer activity in vivo. Mitotic arrest induced by microtubule-interfering agents such as CEUs 
remains the major mechanism of their anticancer activity, leading to apoptosis. However, we recently demonstrated that microtubule disruption by 
CEUs and other common antimicrotubule agents greatly alters the integrity and organization of microtubule-associated structures, the focal 
adhesion contact, thereby initiating anoikis, an apoptosis-like cell death mechanism caused by the loss of cell contact with the extracellular matrix. 
Methods: To ascertain the activated signaling pathway profile of CEUs, flow cytometry, Western blot, immunohistochemistry and transfection 
experiments were performed. Wound-healing and chick embryo assays were carried out to evaluate the antiangiogenic potency of CEUs.  
Results: CEU-induced apoptosis involved early cell cycle arrest in G2/M and increased level of CDK1/cycline B proteins. These signaling events were 
followed by the specific activation of the intrinsic apoptosis pathway, involving loss of mitochondrial membrane potential (Δψm) and ROS 
production, cytochrome c release from mitochondria, caspase activation, AIF nuclear translocation, PARP cleavage and nuclear fragmentation. CEUs 
maintained their efficacy on cells plated on pro-survival extracellular matrices or exhibiting overexpression of P-glycoprotein or the anti-apoptotic 
protein Bcl-2. 
Conclusion: Our results suggest that CEUs represent a promising new class of antimicrotubule, antiangiogenic and pro-anoikis agents. 
Keywords: Aryl chloroethylureas; Mitotic agents; Resistance; Mitochondria; Anoikis. 
 
INTRODUCTION 
N-phenyl-N’-(2-chloroethyl) ureas (CEUs) are low-molecular weight 
compounds that monoalkylate proteins, exhibit antiproliferative 
activity on cancer cells and deeply affect microtubule dynamics 1-
3. CEUs acylate the glutamic acid-198 residue of the mouse β-
tubulin isoform 5 2. The glutamate 198 in β-tubulin was shown to 
be a critical determinant for microtubule stability 4. Competitive 
assays demonstrated that CEU-022 (4-tert-butyl-[3-(2-
chloroethyl)ureido]phenyl) and several CEU drugs acylate human β-
tubulin in a pocket closely adjacent to the colchicine binding site, 
thereby leading to microtubule depolymerization, actin cytoskeleton 
dissolution and, ultimately, cell death 1, 3, 5. As opposed to DNA 
alkylating agents, CEU compounds have been shown as non 
mutagenic and unreactive towards most cellular nucleophiles, such 
as gluthatione and DNA. More recently, we have described that CEU-
022 and CEU-098 (4-iodo-[3-(2-chloroethyl)ureido]phenyl) strongly 
inhibit the migration of endothelial and tumor cells and exhibit 
antiangiogenic properties, which were confirmed in vivo using the 
Matrigel Plug assay in mice and the chick chorioallantoic membrane 
assay (CAM) 1. In addition, the antiproliferative activity of CEU-
022, CEU-098 and, a new prototype, CEU-236 (N-(2-chloroethyl)-N’-
[3-(hydroxypentanyl) phenylurea), was effective in hypoxia-
resistant cells 3.  
The major and common action of microtubule-interfering agents is 
the inhibition of the spindle microtubule dynamics, consequently 
leading to cell cycle blockage at the transition from 
prometaphase/metaphase to anaphase 6. All microtubule-
targeting agents, such as vinca alkaloids, taxanes and epothilones, 
are cytostatic, arresting cells in mitosis, and are not intrinsically able 
to cause cytotoxicity 7. Persistent and sustained mitotic arrest, 
which is poorly tolerated by cells, leads to the disruption of cell 
division and 6, 8, 9 the accumulation of several signals until 
reaching a certain threshold for the onset of apoptosis 10. 
Following antimicrotubule treatment, sustained inactivation of the 
anti-apoptotic protein Bcl-2 through phosphorylation induced by the 
stress-activated MAP kinase ASK1/JNK occurs in cells blocked at the 
G2/M transition. Interestingly, phosphorylation of Bcl-2 and 
activation of the ASK1/JNK pathway are two signaling events 
normally occurring at the G2/M phase of the cell cycle. 
Phosphorylation of Bcl-2 and ASK-1 transiently increase cell 
sensitivity to apoptosis, acting as a mechanism to limit the 
consequences of defects in the spindle structure or aberrant 
chromosomic division 10. By inducing a permanent mitotic arrest, 
microtubule inhibitors therefore induce a permanent activation of 
these apoptotic signals normally occurring transiently during 
mitosis. The stress-activated MAP kinase JNK also phosphorylates 
the BH3-only protein Bim to potentiate its pro-apoptotic activity 
11 and to promote the accumulation of active Bax in the 
mitochondria 12. This phosphorylation allows the release of Bim 
from the microtubule-associated dynein motor complex where it is 
normally sequestered and induces its translocation to mitochondria. 
Thus, Bim binds Bcl-2 and Bcl-xL and promotes apoptosis through 
neutralization of their anti-apoptotic activity or through activation of 
Bax 13. The heterodimerization of Bax with Bcl-2 or Bcl-xL is 
essential to trigger the permeabilization of the outer mitochondrial 
membrane 12, 14 and to mediate the release of pro-apoptotic 
proteins such as cytochrome c, Apaf-1, caspase-9, AIF, Smac/DIABLO 
and HtrA2/Omi to the cytosol 9, 12. Cytochrome c complexes with 
Apaf-1 and caspase-9, known as the post-mitochondrial 
apoptosome, and amplifies the proper activation of effector 
caspases-3, -7 and -6 14. These proteases cleave specific sets of 
cellular and nuclear substrates, such as FAK and Akt 15, resulting 
in the biochemical and morphological changes associated with the 
apoptotic phenotype 9. 
We recently found that CEU derivatives induced focal adhesion 
disorganization, thereby leading to anoikis 5. Anoikis is a rapid 
apoptotic response to an altered cellular environment that is 
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initiated early after inhibition of integrin signaling. The 
molecular mechanisms of anoikis differ among cell types and 
involve diverse apoptotic pathways, such as the activation of the 
JNK pathway and the Fas signaling complex. Interestingly, 
simultaneous pharmacological disruption of actin 
microfilaments and microtubules have led to more pronounced 
cell rounding and enhanced levels of apoptosis, approaching 
those observed during anoikis in fully detached cells 16. During 
cell rounding, the protein kinase Akt/PKB becomes 
dephosphorylated and Bcl-2 expression decreases. The 
disruption of structural elements or change in cell shape that 
alters microtubules and cytoskeletal structures are sufficient by 
themselves to initiate anoikis 16. Accordingly, by serving as 
sensors for microtubules and actin cytoskeleton integrity, the 
pro-apoptotic BH3-only proteins Bim and Bmf were associated 
with anoikis 17. While Bim is sequestered to the microtubule-
associated dynein motor complex, Bmf is sequestered to actin-
associated myosin V motor complex. Loss of cell attachment has 
been shown to unleash Bim and Bmf, allowing them to 
translocate and neutralize prosurvival Bcl-2 proteins 17 or 
induce Bax activation, leading to the activation of the intrinsic 
apoptosis pathway 18. Evidence supports the assumption that 
adhesion-dependent changes in microtubules and cytoskeletal 
structures are hallmarks for the initiation of anoikis/apoptosis 
signal transduction cascade 16. In the present study, we 
describe sustained mitotic arrest induced by CEUs such as CEU-
022, -098 and -236, leading to cell death triggered by loss of 
focal adhesion (anoikis) and apoptosis. We demonstrate a dose-
dependent effect on G2/M cells arrest, tumor proliferation, and 
cell migration mediated by CEUs. We finally show that extra-
cellular matrix (ECM), P-glycoprotein over expression and Bcl-2 
over expression had no protective effect on tumor cell death 
induced by CEUs. 
MATERIALS AND METHODS 
Reagents and Chemicals: N-(2-chloroethyl)-N’-[4-(1,1-
dimethylethyl) phenylurea (CEU-022), N-(2-chloroethyl)-N’-(4-
iodophenyl)urea (CEU-098), N-(2-chloroethyl)-N’-[3-
(hydroxypentanyl) phenylurea (CEU-236) and N-[4-(1,1-
dimethylethyl)-N’-ethylurea (CEU-091) were prepared as published 
previously. All drugs were dissolved in DMSO to make stock 
solutions of 40 mM. DMSO final concentration in the culture medium 
was maintained under 0.2 % (v/v) for each assay. Vinblastine sulfate 
and colchicine were purchased from Sigma (St-Louis, MA) and N-
benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD.fmk) 
from Bachem Bioscience inc. (King of Prussia, PA). Chemicals for 
electrophoresis were purchased from Bio-rad (Hercules, CA) and 
Sigma (St-Louis, MA). 
Cell lines and Culture:  Human skin melanoma M21 cells were 
kindly provided by Dr. David A. Cheresh (The Scripps Research 
Institute, San Diego, CA). HT1080 (human fibrosarcoma), HT-29 
(human colon carcinoma) and MDA-MB-231 (human breast 
carcinoma) cells were purchased from American Type Culture 
Collection (ATCC) and cultured in DMEM supplemented with 5% 
fetal bovine serum. CEM and CEM-VLB cells were kindly provided by 
Dr. William T. Beck and were cultured in RPMI supplemented with 
10% fetal calf serum.  
Antibodies:  Anti-cyclin A, B, and D3, as well as CDK1, CDK2 and 
CDK4, and PARP antibodies were obtained from BD Transduction 
Laboratories (Mississauga, ON). Mouse antibodies against cyclin E 
(HE-12) was purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA), whereas mouse monoclonal cytochrome c antibody (clone 
7H8.2C12) was from BD PharMingen (Mississauga, ON). Rabbit anti-
AIF, anti-Bax (NT) and mouse anti-FAK (clone 4.47) were purchased 
from upstate (Lake Placid, NY). Rabbit Akt (pan) (11E7) was 
obtained from Cell Signaling Technology (Beverly, MA). Mouse anti-
bcl-2 oncoprotein (clone 124) was purchased at Roche (Basel, 
Switzerland). Anti-caspase-3 was obtained from Cell Signaling 
Technology (Beverly, MA). Anti-mouse Alexa 594 and 488 and anti-
rabbit Alexa 488 were from Invitrogen (Burlington, ON). 
Horseradish peroxidase conjugated anti-mouse IgG and anti-rabbit 
IgG were from Amersham Canada (Oakville, Canada). 
Cell Cycle Analysis by Flow Cytometry:  M21, HT-29 and MDA-MB-
231 cells were plated in 100-mm Petri dishes (1.5 X 106 cells/well) 
and were left to adhere at least 24 h. CEU-022 (10, 30 M), CEU-091 
(10, 30 M), CEU-098 (10, 30 M), CEU-236 (10 nM, 50 nM, 100 nM, 
300 nM, 1 M, 10 M) or DMSO (0.12%) was added to the medium 
and incubated at 37 ˚C for 24 h. Afterwards, the adherent cells were 
trypsinized and pooled with the floating cells in cold PBS. The cells 
were next washed with PBS, and fixed in 75% ice-cold ethanol. After 
centrifugation, cell pellets were resuspended in PBS containing 50 
μg/mL of propidium iodide and 200 μg/mL of RNase A for a total 
volume of 500 L. Mixtures were incubated at room temperature for 
30 min, and cell cycle distribution was analyzed with a FACScan 
(FACSCalibur™; Becton Dickinson, San Jose, CA). 
Western Blot Analysis:  The cell cycle protein levels and the 
presence of cleaved PARP, FAK and Akt in situ were evaluated by 
Western blotting with specific antibodies on different cell lines in 
two separate experiments. HT1080, MDA-MB-231 or M21 cells were 
seeded at 5 X 105 cells in 6-well plates and incubated for 16 h. Cells 
were treated with CEU-022 (30, 50, 100 M), CEU-091 (30 M), 
CEU-098 (30 M), CEU-236 (1 M), colchicine (50 nM, 50 M), 
vinblastine sulfate (10 M), or DMSO (0.12 %) for 6, 12, 18, 24, 30, 
48h. After treatments, floating and adherent cells were washed in 
ice-cold PBS, pooled and then solubilized in SDS-PAGE buffer 
containing 62.5 mM Tris pH 6.8, 2 % SDS, 10 % glycerol, 0.00125 % 
bromophenol blue, and 15 % β-mercaptoethanol. The cell extracts 
were then sonicated and boiled for 5 min, separated (15µg) on 8.5 or 
10 % SDS-PAGE electrophoresis gel and transferred onto a 
nitrocellulose membrane. All membranes were blocked and 
incubated with an appropriate dilution of the first antibody. 
Membranes were next washed and incubated with a horseradish 
peroxidase-conjugated goat anti-mouse or anti-rabbit IgG secondary 
antibody (1: 2500) (Amersham Canada, Oakville, Canada) followed 
by chemiluminescent detection, using an enhanced 
chemoluminescence (ECL) detection kit (Amersham Pharmacia 
Biotech). 
Clonogenic Assay:  The capacity of M21 human melanoma cells to 
form colonies was evaluated, after their treatment for 24 h, when 
seeded on plates pre-covered with extracellular matrices or not 1. 
Treated cells were washed, trypsinized and plated at appropriate 
dilutions ranging from 102 to 105 M21 cells per 60-mm Petri dish. 
The experiments were conducted in triplicate to have approximately 
50-200 viable cells per dish. Relative survival was calculated from 
the number of single cells that formed colonies of 50 cells within 12 
days. Survival data were corrected for the plating efficiency of the 
appropriate controls.  
Bidimensional Migration Assay:  MDA-MB-231 human breast 
carcinoma cells were seeded at 3 X 105 cells in 6-well plates and 
incubated 7 h at 37 °C. Cells were treated with DMSO, CEU-022, CEU-
091, CEU-098 or CEU-236 at 0.25, 3 or 5 µM for 16 h at 37 °C. A 
scratch of roughly 1000 µm was performed in the cell monolayer of 
each well. Floating cells were removed and, at different times (0, 3, 6, 
8, 24 h), two pictures of each well were taken to evaluate the speed 
of the wound closure. The breach was measured three times for each 
picture. The migration speed of cells was determined with the slope 
of a graph consisting of the width of the breach as a function of time 
for each treatment and was the mean of two independent 
experiments. 
Chorioallantoic Membrane (CAM) Tumor Assay:  Human HT1080 
fibrosarcoma and hamster CS1 melanoma cell lines were used to 
assess the antitumoral activity of CEU-236 in the chick 
chorioallantoic assay 7. Briefly, day-0 fertilized chicken eggs were 
purchased from Couvoir Victoriaville (Victoriaville, Québec, Canada). 
The eggs were incubated for 10 days in a Pro-FI egg incubator fitted 
with an automatic egg turner before being transferred to a Roll-X 
static incubator for the rest of the incubation time (incubators were 
purchased from Lyon Electric, Chula Vista, San Diego, CA). The eggs 
were kept at 37 °C in a 60 % humidity atmosphere for the whole 
incubation period. Using a hobby drill (Dremel, Racine, WI), a hole 
was drilled on the side of the egg, and a negative pressure was 
applied to create a new air sac. A window was opened on this new 
air sac and was covered with transparent adhesive tape to prevent 
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contamination. A freshly prepared cell suspension (40 L) of 
HT1080 (3.5 X 105 cells/egg) or CS1 (5 X 106 cells/egg) cells was 
applied directly on the freshly exposed CAM tissue through the 
window. On day 11, 100 L of the tested drug (CEU-236, 0, 25, 50, 
100 µg/mL) or the vehicle (mixture of Cremophor EL, 99% ethanol, 
PBS, 1:1:14 v/v) was injected in a blood vessel of the chorioallantoic 
membrane. Each group was composed of 12 eggs. The eggs were 
incubated until day-17, at which time the embryos were euthanized 
by putting at 4 °C followed by decapitation. Tumors were collected, 
pictures were taken to illustrate the different groups, and the tumor-
wet weights were recorded. In all of the experiments, the number of 
dead embryos from the different groups was monitored for any sign 
of toxicity. Results are representative of three independent 
experiments. 
Immunocytochemistry:  To assess the translocation of cytochrome 
c, Bax or AIF, HT1080 human fibrosarcoma or M21 human 
melanoma cells were seeded at 1 X 105 cells per well in 6-well plates 
that contained 22-mm glass coverslips coated with fibronectin (10 
g/mL) and incubated for 24 h at 37 °C. Tumor cells were incubated 
either with CEU-022 (30 M), CEU-098 (30 M), CEU-236 (1 M), 
colchicine (50 nM), vinblastine sulfate (50 nM) or DMSO (0.12 %). 
After 24 h treatments, the cells were washed and fixed with 3.7 % 
formaldehyde in PBS (pH 7.4) for 20 min. They were next 
permeabilized and blocked with 0.1 % saponin and 3 % (w/v) BSA 
in PBS. The cells were further incubated during 1 h at 37 ˚C with 
mouse anti-cytochrome c (clone 7H8.2C12) (1: 200) or with anti-Bax 
or anti-AIF polyclonal antibody (1:150) in a solution containing 0.1 
% saponin and 3 % BSA in PBS. The cells were washed with PBS 
containing 0.05 % Tween 20™ and then incubated 1 h at 37 °C in the 
blocking buffer containing an anti-mouse IgG Alexa-594 (1: 1000) or 
an anti-rabbit IgG Alexa-488 (1:1000) with 4’,6-diamidino-2-
phenylindole and DAPI (2.5 µg/ml in PBS). The cellular distribution 
of the fluorescent cytochrome c, Bax or AIF was assessed using an 
Olympus BX51 microscope. Images were captured as 8-bit tagged 
image format files with a Q imaging RETIGA EXI digital camera 
driven by Image Pro Express software. Data are representative of 
two independent experiments. 
Mitochondrial Membrane Potential (Δψm) and ROS Production 
Analysis by FACS:  HT-1080 human fibrosarcoma cells were seeded 
at 4 X 105 in a 60 mm Petri dish for 12 h. They were next incubated 
at 37˚C with CEU-022 (30 M), CEU-091 (30 M), CEU-098 (30 M), 
CEU-236 (2.5 M), colchicine (100 nM) or vinblastine (5 M) for 24, 
48, 72 h or menadione (100 M/1 h). After treatment, floating and 
trypsinized cells were pooled, washed and then double stained in 
DMEM without fetal bovine serum for 15 min at 37 ˚C with the 
mitochondrial membrane potential sensitive probe DiOC6 (80 nM) 
and 5 µM dihydroethidium (HE), which acquires fluorescence upon 
oxidation with ROS. Treatment with the protonophore carbonyl 
cyanide m-chlorophenylhydrazone (CCCP) (100 M/15 min) was 
used as negative control for DiOC6 staining while menadione (100 
M/1 h), a redox cycling agent that produces ROS in the presence of 
O2, was a positive control for the oxidation of HE. Fluorescence was 
assessed by FACScan analysis (FACSCalibur™; Becton Dickinson, San 
Jose, CA) in FL-1 (520  20 nm) for DiOC6 and FL-3 (620  20 nM) for 
ethidium (Eth), the oxidized form of He. Dot plot analyses were 
performed with the WinMDI 2.8 program (J. Trotter, The Scripps 
Institute, La Jolla, CA) and obtained from the fluorescence data of 
10000 individual cells. Cells were gated to eliminate fragments and 
doublets with the forward (FS) and side (SS) light scatter analysis 
that detects modifications of cell size and granularity, respectively. 
Quadrant was positioned according to the 24 h untreated dot plot to 
evaluate the percentage of changes in fluorescent cell distribution. 
The changes in optical properties of cells (size and granularity), 
reminiscent of cell viability loss, were determined according to the 
region of the 24 h untreated sample where most of cells (85%) are 
distributed (green), and represented on the dot plot with different 
colors in reference to this cell population: dark blue, diminution of 
size and granularity; pink, diminution of size and increase of 
granularity; pale blue, increase of size and granularity. 
Mitochondrial Electron Microscopy Analysis:  Transmission 
electronic microscopy was performed on MDA-MB-231 cells 
exposed to CEU-236 (1 M) or DMSO (0.08 %) for 24h. Once 
harvested, cells were fixed 1h at 4 °C with a fixation buffer 
containing paraformaldehyde 2 %, glutaraldehyde 2.5 %, phosphate 
buffer 0.1 M pH 7.3 and calcium chloride 3 mM. Cells were washed 
twice with phosphate buffer 0.1 M pH 7.3 for 30 minutes then 
washed overnight in the same buffer. They were next fixed for a 
second time for 90 minutes with the same fixation buffer to which 
osmium tetroxide 1 % was added. The fixed cells were dehydrated 
with ascending alcohol concentrations, up to 100 %, followed by two 
propylene oxide incubations of 30 minutes. Cells were next 
embedded with an epoxy resin and then cured 1 day at 37 °C, 
followed by 3 days at 60 °C. Afterward, these samples were finely 
sliced (thickness of 80 nM) and placed on nickel/formvar grids (200 
mesh), before being stained with lead citrate and uranil acetate. 
They were finally analyzed using a transmission electron 
microscope JEOL1230 (JEOL, Boston, Massachusetts, USA) under 
80KV acceleration voltage at 6 X 104 and 12 X 104 magnification. 
Scale bars represent 2 m and 100 nm for 6 X 104 and 12 X 104 
magnifications, respectively. 
Growth Inhibition Assay with CEM: The growth inhibition potency 
of CEUs, colchicine, vinblastine and taxol® was assessed using the 
procedure described by the National Cancer Institute for its drug 
screening program 19. 96-well microtiter plates were seeded with 
3.5 X 103 CEM and CEM-VLB cells suspended in 100 μL of RPMI 
supplemented with 10% fetal bovine serum. Drugs freshly 
solubilized in DMSO were diluted in culture medium and aliquots of 
100 μL containing sequential dilution of drugs were added. Final 
drug concentrations ranged from 100 to 1 μM for CEU-022, -091, -
098, from 100 to 0.01 μM for CEU-236, from 100 μM to 0.1 nM for 
colchicine and from 1 μM to 0.01 nM for vinblastine. Plates were 
incubated for 48 h. The incubation was stopped by addition of cold 
trichloroacetic acid to the wells (10 % final concentration), followed 
by incubation for 1 h at 4 °C. Plates were washed five times with 
water. Sulforhodamine B solution (50 μL) at 0.1 % (w/v) in 1 % 
acetic acid was added to each well, and plates were incubated for 15 
min at room temperature. After staining, unbound dye was removed 
by washing five times with 1 % acetic acid. Bonded dye was 
solubilized with 10 mM Tris base, and the absorbance was read 
using a μQuant Universal Microplate Spectrophotometer (Biotek, 
Winooski, VT) at 585 nm. Background optical density from a control 
reference plate fixed on the day of treatment was subtracted from 
the O.D obtained with the 48-h growth period. The growth inhibition 
percentage was calculated in reference to DMSO treated cells for 
each drug concentrations. The results were obtained from at least 3 
separate experiments. The GI50 assay was considered valid when the 
variability among data for a given set of conditions, within the same 
experiment, was less than 10 % with respect to the mean value. 
Extracellular Matrices (ECMs):  Native (Col IV) and heat-denatured 
type IV collagen (HdCol IV) (50 µg/ml), fibronectin (FN) (25 µg/ml), 
fibrinogen (Fg) and fibrin (Fb) (50 µg/ml) were used to coat non-
adherent tissue culture plates (Nunc). After washes with serum-free 
DMEM, M21 cells were plated in serum-containing or serum-free 
media on the different matrices and incubated overnight. Moreover, 
5 X 105 cells were plated in 6-well plates for Western blot analysis of 
FAK, Akt and PARP and 1 X 106 cells were plated in 100-mm Petri 
dishes coated with different ECMs. Forthwith, M21 cells were 
challenged with CEU-022 (100 µM), colchicine (50 µM) and 
vinblastine (10 µM) for Western blot analysis or CEU-022 (20 µM) 
for clonogenic assay. Representative data resulting from two 
independent experiments performed in triplicate are shown. 
Plasmid, Transfection and Cell Viability Assay: The pEGFP-C3-
hBcl-2 (EGFP-Bcl-2) construct was kindly provided by Dr. Richard J. 
Youle. HT1080 cells were seeded at 1 X 106 cells per 60 mm dish and 
incubated 12 h at 37 °C. They were next transfected with 0.5 g/mL 
of each plasmid and 4 L of the FuGENE 6 reagent per g of pcDNA3 
or pEGFP-C3-hBcl-2, according to the manufacturer’s instructions 
(Roche Diagnostics, Indianapolis, IN). Twenty-four hours post-
transfection, cells (3500/well) were seeded in 96-well plates and 
incubated at 37 °C for 5 h. Fresh medium containing DMSO, CEU-022 
(20 µM), CEU-091 (20 µM), CEU-098 (20 µM), CEU-236 (1 µM), 
colchicine (15 µM) or vinblastine (10 nM) was added, and cells were 
further incubated at 37 °C for 24 h. Resazurin (25 g/mL) was next 
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added to the culture medium for 1 h at 37 °C. Cell viability was 
calculated from fluorescence (excitation, 530 nm; emission, 590 nm) 
measured with a FL 600 Reader (Bio-Tek Instruments, Winooski, 
VT). Data from experiments conducted in triplicate were corrected 
for the background fluorescence of the medium and were expressed 
as the mean percentage of fluorescence obtained for control DMSO-
treated cells. They are representative of two independent 
experiments. 
RESULTS 
Mitotic Arrest and CDK1/cyclin B Expression Level Induced by 
CEUs: We first evaluated and compared the antimitotic potency of 
CEUs by assessing their effect on the cell cycle using three different 
types of cancer cell lines (MDA-MB-231, M21 and HT-29). Cells were 
treated with different concentrations of each drug. CEU-022 and 
CEU-098 are bioisosteric derivatives while CEU-091 is the non-
alkylating counterpart of CEU-022.  
 
Fig. 1: Mitotic arrest (A, B, C) and increased of CDK1/cyclin B 
expression level (D) in response to CEUs. 
CEU-236 exhibits a bulky and polar substituent at the position 3 of 
the aromatic moiety (Figure 1A). As was previously shown for 
antimicrotubule agents such as vinca alkaloids and taxanes, β-
tubulin alkylating CEU-022 and CEU-098, CEU-236 also blocks cell 
division at the G2/M phase (Figure 1A and B). However, CEU-91 did 
not seem to have any effect on the cell cycle at 10 µM and 30 µM 
CEU-091. MDA-MB-231, M21 and HT-29 cell accumulation in G2/M 
phase were observed at 10 µM and were predominant at 30 µM for 
CEU-022 and CEU-098 (Figure 1B). CEU-236 exhibited strong 
accumulation in G2/M phase at concentrations lower than its 
counterparts (1 and 10 µM). Dose-dependent analysis of CEU-236, 
illustrated in Figure 1C, demonstrates that the G2/M block occurred 
at 500 nM and is maximal when using 1 M for the three cancer cell 
types. Afterwards, we analyzed kinetic protein levels of different 
cyclins and CDKs on MDA-MB-231cells treated with CEUs (Figure 
1D). In comparison to the control DMSO, antimitotic CEUs, notably 
compounds CEU-022 and -236, induced an increase in the cyclin 
B/CDK1 protein levels and a decrease in the cyclin D3/CDK4 protein 
levels; these changes generally started 12 to 24 hours after 
treatment. Antimitotic CEUs did not induce significant changes in 
cyclin A (Figure 1D) or in CDK2 and cyclin E protein levels (data not 
shown). 
CEUs are Potent Cytotoxic and Antiangiogenic Agents: Several 
CEUs were previously shown to not only inhibit cancer cell 
proliferation, but also abrogate endothelial cell migration 1, 3. We 
therefore completed dose-dependent studies to compare CEU effects 
on cell growth and migration (Figure 2). Clonogenic assays showed 
that CEU-022 and CEU-098 exhibit a strong inhibition on cancer cell 
growth at 30 M and CEU-236 at 5 µM. While CEU-091 seemed to 
have little impact, CEU-236 had the highest cell growth inhibition 
potency on M21 cells as compared to other CEUs, colchicine and 
vinblastine (Figure 2A). The bidimensional assay performed using 
the highly mobile MDA-MB-231 cells showed that CEU-236 
displayed a strong motogenic inhibition on the evaluated tumor cells 
(Figure 2B). While CEU-022 and CEU-098 diminished MBA-MB-231 
migration at 5 M, a subcytotoxic concentration, CEU-236 had 
similar effects at much lower concentrations (0.5 M) and impeded 
both cell growth and migration at 5 M. Of note, CEU-091, which is 
devoid of alkylating moiety, neither impeded M21 cell growth nor 
MBA-MB-231 cell migration. 
 
Fig. 2: Antimitotic CEUs display anti-proliferative (A), anti-
migration (B) and anti-tumoral (C) properties.  
ANOVA test showed a significant difference between doses (P  
0.01). Dunnett test was performed (, P  0.05; and , P  0.01). 
The strong anti-proliferative and anti-motogenic potency of CEU-
236 prompted us to evaluate the growth of solid tumors in the chick 
CAM model (Figure 2C). The growth of solid tumors on the surface of 
the CAM depends on its ability to stimulate angiogenesis and to grow 
significantly in 7 days. CS1 hamster melanoma and HT1080 human 
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fibrosarcoma cell lines were used for their potency to produce solid 
tumors sensitive to antiangiogenic and antitumoral therapy 1. 
Incubation of CS1- and HT1080-derived tumors on the CAM with 
CEU-236 reduced significantly the tumors size in a dose-dependent 
manner (Figure 2C), as previously published for CEU-022 and -098 
1. Both CS1- and HT1080-derived tumor masses were inhibited by 
CEU-236 in the same concentration range. Interestingly, the tumor 
masses were devoid of grossly visible blood vessels as compared to 
the vehicle (data not shown). The concentrations of CEU-236 used 
appeared to be well tolerated by the chick embryos since no 
mortality was observed. 
CEUs Promote Bax Translocation to Mitochondria: Antimitotic 
CEUs, like other commonly used antimicrotubule drugs, have been 
shown to reduce cellular adhesion and provoke disorganization of 
focal adhesion and actin stress fibers that precedes the onset of 
anoikis 5. We demonstrated that sustained phosphorylation of 
paxillin required the activation of p38 5.  
 
Fig. 3: CEUs induce Bax mitochondrial translocation (A), 
cytochrome c release (B), nuclear condensation and 
fragmentation (B). 
Herein, we studied the mitochondrial sequence of events leading 
to anoikis with our compounds. Bax, a member of the Bcl-2 
protein family, plays a key role in the mitochondrial potential 
lost, the formation of transition pores and the release of 
apoptotic protein mediators such as cytochrome c and AIF in 
response to different stimuli, such as the increase of reactive 
oxygen species (ROS), thiol oxidation and loss of the 
mitochondrial membrane potential (Δψm) 20. Phosphorylation 
of Bim is required to induce the translocation of Bax into the 
mitochondria 11, 13. We analyzed the localisation of Bax 
following 24 h treatments of M21 melanoma cells (Figure 3A). 
Bax translocation into the mitochondria of M21 cells occured in 
response to CEU-022, CEU-098 and CEU-236. Colchicine and 
vinblastine induced the translocation of Bax into the nucleus. 
This translocation occurred to a lesser extent in cells treated 
with DMSO. 
CEUs Induce the Onset of the Classical Apoptosis Pathway: 
Cytochrome c Mitochondrial Release, Nuclear Condensation and 
Fragmentation: We have shown previously 1 and herein that 
CEUs inhibit cell proliferation and are cytotoxic, as demonstrated in 
clonogenic assay. We investigated whether the common effectors of 
cell death, such as cytochrome c mitochondrial release, mediated the 
cytotoxic activity of CEUs. In a first set of experiments, we showed 
that cytochrome c localization was critically modified following CEU-
022, -098 and -236 treatments in HT1080 (Figure 3B). The release of 
cytochrome c from mitochondria was also observed with MDA-MB-
231 cells (data not shown). Furthermore, nuclear condensation and 
fragmentation occurred following exposure to any of the antimitotic 
CEUs used in the present study (Figure 3B).  
CEU-Treated Cells Exhibit Loss of Mitochondrial Membrane 
Potential, ROS Production and Mitochondrial Morphological 
Alterations: ROS production and loss of membrane potential 
(Δψm) are two manifestations that occur during the early phase 
of apoptosis 20. We monitored the Δψm and the ROS production 
changes in HT1080 cells with the cationic DiOC6 and 
dihydroethidium (HE) probes, respectively. Treatment with the 
protonophore carbonyl cyanide m-chlorophenylhydrazone 
(CCCP) (100 M/15 min) was used as negative control for DiOC6 
staining. Menadione (100 M/1 h), a redox cycling agent that 
produces ROS in the presence of O2, was selected as a positive 
control for the oxidation of HE. Anti-mitotic CEUs (except CEU-
091) led to a drop in Δψm and an increase in ROS production 
(Figure 4A); changes were similar in the other anti-microtubule 
agents tested (vinblastine and colchicine). ROS production was 
observed 24 h following antimitotic CEUs, and was markedly 
with CEU-236, colchicine and vinblastine conditions. The loss of 
Δψm started 24 h after CEUs colchicine and vinblastine 
treatments and increased greatly after a treatment of 48 and 72 
h. CEU-236 exhibited a pattern similar to that of colchicine and 
provoked a marked reduction of the cell size. The reduction of 
cell size and granularity was indicative of an increase in cell 
mortality at 48 and 72 h following CEUs, colchicine and 
vinblastine treatment. We then observed the appearance of 
mitochondria in MDA-MB-231 cells using electronic microscopy 
to investigate the capacity of CEU-236 to initiate apoptosis. 
MDA-MB-231 cells treated with DMSO for 24 h showed 
ultrastructural details representative of normal cells, with no or 
negligible changes seen in the mitochondria (Figure 4B). 
Progressive damage to MDA-MB-231 cells treated with CEU-236 
(1 µM) was obvious after 24 h, and multiple mitochondria 
showed marked swelling as well as typical large matrix 
compartments (Figure 4B). 
 In some cells, this process progressed to a final stage, with extensive 
vacuolization and nuclear pyknosis. The characteristic condensation 
and peripheral margination of nuclear chromatin, hallmarks of 
apoptosis, were observed following CEU-236 treatment. 
CEUs Provoke PARP Cleavage and AIF Nuclear Translocation. 
Cleavage-dependent activation of the initiator caspase-9 and 
caspase-8 are hallmarks for the initiation of apoptosis. Previous 
studies showed the activation of caspase-9, -6, -7, -3, -8, and 
PARP cleavage following CEU-022, CEU-098 and CEU-236 
treatments 3, 5. To determine the contribution of caspase 
activation on PARP cleavage in response to antimitotic CEU 
treatments, HT1080 cells were pretreated for 1 h with the 
caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-
fluoromethylketone (zVAD.fmk) (Figure 5A and B). Pretreatment 
with zVAD.fmk decreased the cleavage of PARP for CEU-022, 
CEU-236 and colchicine (Figure 5B). Those observations were 
noticed in a lesser extend with CEU-098. For the colchicine 
conditions the PARP protein level expression increased with the 
decrease in cleaved protein following zVAD.fmk pretreatment as 
compared to the non-pretreated cells. 
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Fig. 4: Loss of mitochondrial membrane potential (Δψm) and 
ROS production induced by CEUs using (A) FACScan and (B) 
transmission electronic microscopy analysis of 
mitochondria. 
The proper use of the caspase inhibitor is shown in Figure 5A, 
which demonstrates the reduction in caspase-3 cleavage in 
zVAD.fmk pretreated cells. Since nuclear condensation was 
observed following CEU treatment (Figure 3C) and knowing that 
AIF triggers nuclear condensation, we further evaluated whether 
the intracellular localization of AIF in M21 changed after the 
exposition to antimitotic CEUs. Immunocytochemistry showed 
that CEUs induced AIF nuclear translocation in a fashion similar 
to colchicine, but less than vinblastine (Figure 5C). 
 
Fig. 5: CEUs induce the proteolytic cleavage of proteins 
associated with apoptosis (caspase-3 (A), PARP (B)) and AIF 
nuclear translocation (C). Double and single arrows indicate the 
native and cleaved protein respectively. 
P-glycoprotein, ECMs, or Bcl-2 Overexpression do not Protect 
Cells From CEUs: Previous studies demonstrated that CEU-022 
exhibits equivalent anti-proliderative activity in cells with either P-
glycoprotein overexpression, increased intracellular concentration 
of gluthatione and/or glutathione-S-transferase activity, altered 
topoisomerase II activity or increased DNA repair mechanisms. The 
multidrug resistance phenotype (MDR1) mediated by P-glycoprotein 
(Pgp) is an important mechanism of resistance to the microtubule-
targeting drugs such as vinca alkaloids and taxanes, as well as a 
broad range of other classes of anticancer agents 4. We therefore 
used cells overexpressing P-glycoprotein (CEM-VLB) or not (CEM) 
and treated them with common antimitotics and CEUs (Figure 6). 
CEU-098, CEU-236 remained potent antiproliferative agents even in 
CEM-VLB cells, as opposed to colchicine, vinblastine. 
 
Fig. 6: CEUs display cytotoxic activity on cells exhibiting P-
glycoprotein overexpression (MDR1). 
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The tumor microenvironment can modulate the ability of tumor cells 
to overcome antineoplastic treatment, such as cisplatin, and involves 
integrins to trigger prosurvival signals 18. The CAM-DR phenotype 
is caused by integrin/extracellular matrix (ECM)-induced pro-
survival signal. We evaluated the potency of CEU-022, as a 
representative of other potent CEUs, colchicine and vinblastine to 
trigger FAK, Akt and PARP cleavage in M21 cells seeded on different 
extracellular matrices (ECMs): native (Col IV) and heat-denatured 
type IV collagen (Hd), fibronectin (FN), fibrinogen (Fg) and fibrin 
(Fb) (Figure 7A). ECMs reduce PARP cleavage for colchicine- and 
vinblastine-treated cells. FAK and Akt cleavage were totally inhibited 
by the presence of ECMs after colchicine and vinblastine exposure. 
Interestingly, CEU-022 induced FAK, Akt and PARP cleavage under all 
conditions tested (Figure 7A) and abrogated significantly the survival of 
M21 cells seeded with ECMs fibrin, fibrinogen and native collagen 
compared to the condition without FBS and matrix (Figure 7B). 
 
Fig. 7: ECM does not protect cells from CEU-022 damage, such as 
FAK, Akt and PARP cleavage (A) and cell death (B).  
Dunnett test was performed ( P  0.01) for comparison with the 
condition without FBS and matrix. 
The Bcl-2 oncoprotein can inhibit apoptosis induced by antitumor 
agents at a point downstream of drug-target interactions 9. The 
ability of Bcl-2 to enhance cell viability (Figure 8) was studied with 
PEGFP-Bcl-2 transfected HT1080 cells. As depicted in Figure 8, Bcl-2 
protein overexpression significantly increased cell viability 
following exposure to colchicine for 24 h, but not following exposure 
to CEU-022, CEU-098 or CEU-236. CEUs maintained their anti-
proliferative activity in both transfected cell populations (pcDNA3 
and pEGFP-Bcl-2). 
 
Fig. 8: CEUs are unaffected by Bcl-2 overexpression. 
DISCUSSION 
Our results showed that the major signaling route underlying the 
anti-proliferative action of CEUs is similar to the other well-known 
anti-microtubule agents, including colchicine and vinblastine 8. As 
opposed to these classical agents, CEUs bind covalently and 
irreversibly to β-tubulin through an acylation reaction 2. While 
paclitaxel stabilizes microtubule dynamics, colchicine and 
vinblastine destabilize microtubules and prevent further addition or 
loss of subunits 8. Colchicine forms a tubulin-drug complex, which 
then copolymerizes into the microtubule ends, thus suppressing the 
microtubule dynamics even when their ends remain competent to 
grow. On the other hand, CEUs bind the soluble-β-tubulin pool and 
inhibit microtubule growth. 
As with other commonly used antimicrotubule agents, CEU-022, 
CEU-098 and CEU-236 provoke a G2/M cell cycle arrest. Herein, we 
showed a dose-dependent increase in the percentage of cells 
accumulated in the G2/M cell cycle phase. Antimicrotubule drugs 
block the proteasome-dependent degradation of cyclin B1, resulting 
in a sustained activation of cyclin B1/cdc2 kinase and a cell cycle 
arrest in mitosis. Likewise, these agents induce also an up-regulation 
of cyclin B1 and CDK1/cdc2 proteins and stimulate their activity. 
The CDK1/cyclin B protein levels raised in accordance with the 
blockage observed in G2/M. However, the population of cells in the 
G0/G1 phase diminished, with a progressive accumulation of cells 
arrested in G2/M phase (data not shown), consequently the 
CDK4/cyclin D3 protein level was reduced (Figure 1).  
Except for CEU-236, CEUs are cytotoxic at doses higher than other 
common anti-mitotic agents (Figure 2A). However, they induce 
mitotic arrest (Figure 1A, 1B) in the same concentration ranges as 
their anti-proliferative activity (Figure 2A). This is not the case for 
other common antimicrotubule agents, including colchicine and 
vinblastine, which are not cytotoxic at anti-proliferative doses (nM 
range) 21, 22. Accordingly, efficient repolymerization of 
microtubules has been shown to restore normal cell cycle and 
growth during the long lag phase observed between microtubule 
disruption by those drugs and the onset of apoptosis 8. This 
highlights the importance of timing in signaling and duration to 
achieve a final outcome with these drugs 8. Noteworthy, due to 
irreversible and covalent binding to β-tubulin, cells exposed to anti-
proliferative doses of alkylating CEUs cannot be rescued 5. 
Some microtubule-disrupting agents act on tumor vasculature and 
inhibit angiogenesis. At low-dose and non-cytotoxic concentrations, 
proliferation, adhesion and migration of human endothelial cells 
have been shown reduced by potent antimicrotubule agents such as 
colchicine, vinca alkaloids and taxotere 21, 22. Compared to 
normal and cancer cells, vascular endothelial cells were 
preferentially affected by continuous low-dose exposure to the 
drugs that exhibit antiangiogenic properties in several in vitro 
models 21, 22. Clinical application of a continuous low dose of 
these agents has thus been suggested as an optimal way of 
delivering antiangiogenic cancer therapy 22. The efficacy of 
classical microtubule-targeted agents as either antiproliferative 
agents or as vascular-targeting agents might reside in their 
pharmacokinetic and pharmacodynamics characteristics, the 
reversibility of their binding to tubulin and their lack of long-term 
retention in cells. Agents that enter cells, depolymerize microtubules 
and are metabolized or excreted rapidly might act best as 
antivascular agents. Those that are retained in cells and induce long-
term mitotic block might work best as antiproliferative agents that 
induce apoptotic cell death, such as CEU-022 and CEU-098. 
Interestingly, CEU-236 exhibited both anti-motogenic and cytotoxic 
potency in the micromolar range (Figure 2A, 2B). We evaluated the 
antiangiogenic and antitumor potency of CEU-236 in the chick 
embryo CAM assay. CEU-236 diminished significantly the tumor size, 
as observed previously with CEU-022 and CEU-098 1. Tumors 
were also devoid of obvious blood vessels (data not shown), also 
supporting that antimitotic CEUs have both potent antiendothelial 
and antitumor cell activity in vivo 1. 
The focal adhesion disassembly in response to CEUs, in addition to 
the mitotic spindle disruption, may contribute significantly to reach 
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the cellular threshold for the onset of apoptosis through anoikis 5, 
8, 9. We therefore investigated the mechanisms underlying the 
adhesion impairment and the cytotoxic properties of CEUs. 
Antimitotic CEUs trigger apoptosis involving, in part, the release of 
cytochrome c from the permeability transition pore complex (PTPC) 
in the external membrane of the mitochondria. Cytochrome c plays 
an essential role in apoptosis, as shown in cell lines from mice that 
have a disrupted gene and are refractory to apoptosis induced by 
stimuli that affect mitochondria 14. However, cytochrome c release 
alone does not appear to be sufficient to trigger apoptosis 14. 
Following classical anti-mitotic treatment, it has been described that 
Bim, inducing the oligomerization of BAK and Bax, leads to 
cytochrome c release 14. The CEUs tested herein provoked Bax 
translocation into the mitochondria, leading to subsequent 
cytochrome c release. The translocation of Bax is accompanied by 
apparent changes in Bax conformation, unmasking its N-terminus 
and resulting in Bax oligomerization, which promotes the 
permeabilization of the outer mitochondrial membrane 14. 
Released intermembrane space proteins included cytochrome c, 
which complexes with Apaf-1 (apoptotic protease-activating factor 
1) and caspase-9 to form a post-mitochondrial apoptosome that 
amplifies effector caspase activation 14. M21 cells treated with 
colchicine or vinblastine also induced Bax translocation into the 
mitochondria, as did CEUs. Cells treated with colchicine or 
vinblastine also have high levels of Bax protein levels in their 
nucleus (Figure 3B). Translocation of Bax into the nucleus during 
apoptosis has previously been reported after exposure of cells to 
hyperthermia. Bax may play an important role both within the 
nucleus in the early phase of apoptosis as well as in the 
mitochondrial membrane. 
Variations in mitochondrial membrane potential (Δψm) are key 
events during drug-induced apoptosis 20. Herein, we described 
that CEU-236, the most potent of the anti-mitotic CEUs tested, 
induced ROS production, loss of Δψm, and mitochondrial swelling. 
We demonstrated the translocation of the mitochondrial protein AIF 
(apoptosis-inducing factor), a caspase-independent death effector, 
into the nucleus of CEU-treated M21 cells. Nuclear condensation and 
fragmentation were observed after CEU treatment. Furthermore, a 
previous study demonstrated that the initiator caspase-9 is cleaved 
rapidly after CEU or colchicine treatment (as early as 6 hours for 
CEU-098 and CEU-236), and the effector caspases (-3, -6 and -7) 
followed in the next hours 5. Such a sequence of activation is 
coherent with a caspase-mediated cell death. Pro-survival proteins 
such as FAK, Akt and PARP were cleaved following anti-mitotic and 
CEU treatments 3, 5. Thus, for those compounds, mitochondria 
play a key role in the control of cell death execution 14. Altogether, 
these observations indicate that CEUs induce apoptosis in cancer 
cells. 
We then treated with our compounds a variety of cancer cells, which 
normally exhibit mechanisms of resistance towards anticancer 
treatment. Drug resistance is a major factor hampering the clinical 
anti-cancer efficacy of microtubule targeting agents. The multidrug 
resistance phenotype mediated by P-glycoprotein (Pgp) is an 
important mechanism of resistance to the microtubule-targeting 
drugs vinca alkaloids and taxanes, as well as a broad range of other 
classes of anti-cancer agents 8. These drugs are excluded from cells 
expressing p-glycoprotein and its overexpression results in 
resistance to these compounds. This probably constitutes the most 
efficient mechanism for cancer cells to achieve resistance to many 
structurally and mechanistically unrelated drugs, a phenomenon 
known as multidrug-resistance (MDR) 6. Herein, we demonstrated 
that antimitotic CEUs preserve their growth inhibition properties in 
the presence of Pgp overexpression (Figure 6).  
Previous studies report that the cytotoxicity of cisplatin could be 
reduced by ECMs such as collagens, fibronectin and laminins, which 
are integrin ligands. There is an increased recognition that different 
ECMs abrogate the efficacy of anticancer drugs. This mechanism is 
named the CAM-DR phenotype and is caused by 
integrin/extracellular matrix (ECM)-induced pro-survival signals. 
We demonstrated that the cytotoxicity of CEU-022 (used as a 
representative member of this class) was unaffected by fibrin and 
fibrinogen matrix, as opposed to cisplatin 1. Herein, we 
demonstrate that apoptotic signaling events, such as FAK, Akt and 
PARP cleavage, remain strongly present in cells seeded on ECM and 
treated with CEU-022, in contrast to colchicine and vinblastine 
treatment. Moreover, CEU-022 provoked the death of M21 cells 
seeded or not on the different ECMs. Cells that overexpress the pro-
survival proteins Bcl-2 and Bcl-XL are highly resistant to anoikis 
17. Interestingly, anti-mitotic CEUs preserve their antiproliferatic 
activity in cells transfected with pEGFP-Bcl-2. On the other hand, 
there was a significant inverse correlation between growth 
inhibition by colchicine and Bcl-2 levels. Bcl-2 serves as a powerful 
antidote to cell death and may countermand the effect of both 
caspase-dependent and independent modes of cell death through 
manifold-independent functions such as the abrogation of 
cytochrome c release from mitochondria, the regulation of calcium 
homeostasis, the promotion of glutathione sequestration to the 
nucleus, and the modulation of antioxidant pathways. 
In conclusion, we identified unique properties of antimitotic CEUs, 
which are β-tubulin acylating agents and promising antineoplastics. 
We have shown previously that antimitotic CEUs display a sustained 
inhibition of the β-tubulin polymerization and a parallel 
dismantlement of focal adhesion 5, 24. Herein, we demonstrated 
that these events lead to the production of ROS and loss of 
mitochondrial membrane potential. The mitochondrial translocation 
of Bax following CEU treatments, which is known to be involved in 
the formation of a permeability transition pore 11-13, 23. These 
events are followed by classical apoptotic features such as the 
release of mitochondrial cytochrome c and AIF, caspase activation, 
pro-survival protein cleavage, and nuclear condensation and 
fragmentation (Figure 9) 9. Antimitotic CEUs preserve their anti-
proliferative activity against MDR resistance phenotype, CAM-DR 
pro-survival signal, and Bcl-2 overexpression. Moreover, we 
demonstrated that CEU-236 is a potent anti-proliferative and anti-
motogenic agent in the micromolar range. CEU-236 is active in the 
chick embryo CAM and is 20-fold more potent than most of the 
previously prepared CEUs. This compound is of utmost interest 
since the presence of oxygenated group(s) significantly alters the 
physicochemical properties of the drugs and probably results in a 
different biodistribution profile from that of CEU-022 and CEU-098. 
The pharmacomodulation of CEU-236 therefore opens a new area of 
research and medical application. 
 
Fig. 9: Proposed biochemical pathway for anti-mitotic CEUs 
induced apoptosis. 
Anti-mitotic CEUs alkylate β-tubulin and induce a stress on the 
cytoskeleton inducing changes such as actin contraction. The 
dissociation of ASK-1 and thioredoxin-1 (Trx-1) complex occurs in 
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cells treated with anti-mitotic CEUs 24. Ask-1 is subsequently 
phosphorylated and triggers the phosphorylation of JNK and P38. 
Consequently, paxillin phosphorylation by the MAPKs leads to focal 
adhesion disorganization. In addition, the antiapoptotic protein Bcl-
2 and the pro-apoptotic BH3-only protein Bim are phosphorylated 
and mitochondrial translocation of Bax occurs. Cytochrome c, 
procaspase-9 and Apaf-1 are released from mitochondria and form a 
complex leading to caspase activation. Prosurvival proteins such as 
FAK and Akt are cleaved through the activated caspases. These 
events lead to apoptosis and anoikis. 
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